Pharmacologic class (EPC) · 2 drug pages

Prostacyclin receptor agonist: adverse event reports filed with FDA

19,293 reports list a drug in this class as a suspect or interacting product, 2012–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

19,293
reports across the class: 0.1% of all reports; 1,030
reports, 12 months to June 2026: 1,194 in the 12 months before; 76.8%
marked serious by the reporter: 57.4% across all reports; 2
drugs with a page: brand and generic names counted separately

Prostacyclin receptor agonist is a pharmacologic class (an FDA Established Pharmacologic Class) with 2 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 19,293 adverse event reports received by FDA, 0.1% of the database, from May 2012 to June 2026.

1,030 reports arrived in the 12 months to June 2026, down 14% from 1,194 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 76.8% of the class's reports are marked serious, 20.3% record death among the outcomes and 50.5% record hospitalisation, as reported.

Across the class the reactions recorded most often are headache (30.5%), diarrhoea (23.3%) and dyspnoea (19.8%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
Uptravi	generic	16,976	955	74.8%	Headache
Selexipag	generic	2,317	75	91.7%	Headache

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Headachehead pain30.5%5,879
Diarrhoealoose or frequent stools23.3%4,491
Dyspnoeashortness of breath19.8%3,817
Nauseafeeling sick18.1%3,492
Pain in jaw11.1%2,146
Fatiguetiredness10.9%2,098
Deaththe patient died; cause not stated by this term10.1%1,942
Painpain, site not specified10%1,934
Dizzinesslight-headedness or unsteadiness9.6%1,858
Pain in extremitypain in an arm or leg9.6%1,858
Myalgiamuscle pain9.4%1,816
Vomitingbeing sick8.4%1,629
Malaisegeneral feeling of being unwell8%1,541
Pulmonary arterial hypertension7.5%1,445
Hypotensionlow blood pressure7.5%1,442
Arthralgiajoint pain7.4%1,432
Pneumonialung infection7.3%1,418
Decreased appetitereduced appetite6.3%1,216
Hospitalisationadmission to hospital6.1%1,185
Fluid retentionthe body holding extra fluid5.5%1,068
Condition aggravatedthe condition being treated got worse5.4%1,048
Dyspnoea exertional5.1%978
Astheniaweakness or lack of energy5%969
Coughcough5%965
Flushingsudden reddening or warmth of the skin4.9%953

Solid bar: share of all class reports. Hollow bar: the median share across the 2 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death20.3%3,917

Life-threatening1.8%340

Hospitalisation (initial or prolonged)50.5%9,744

Disability1.2%226

Congenital anomaly0.1%11

Other serious29.9%5,775

Not serious23.2%4,475

Patient age

Under 20.2%48

2 to 111.1%204

12 to 171.1%217

18 to 4411.8%2,273

45 to 6426.6%5,140

65 to 7419.2%3,704

75 and over14.9%2,875

Age not given25%4,832

Who reported

Physician27.5%5,311

Pharmacist4.3%835

Other health professional47.4%9,138

Lawyer0%1

Consumer or non-health professional20.7%3,994

Not given0.1%14

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Prostacyclin receptor agonist reports

Which drugs are in the Prostacyclin receptor agonist class on this site?

Uptravi and Selexipag. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

19,293 reports through June 2026, 1,030 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

headache (30.5%), diarrhoea (23.3%), dyspnoea (19.8%), nausea (18.1%) and pain in jaw (11.1%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.